Yahoo Finance

Intersect ENT (XENT) Receives CE Mark for PROPEL Contour

Intersect ENT Inc. XENT recently received CE Mark approval for its PROPEL Contour (mometasone furoate) sinus implant. This authorization permits the sales and distribution of this third localized drug ...
Nasdaq

Intersect ENT Receives CE Mark Approval for PROPEL® Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery

Localized steroid-releasing sinus implant designed to maintain sinus opening now available in select EU countries PROPEL Contour features an innovative hourglass shape, specifically designed for ...
Business Wire

EXPAND Post-Market Study Evaluating Longer-Term Outcomes of PROPEL® Contour Sinus Implant in the Frontal Sinus Ostia Following In-Office Balloon Sinus Dilation

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that ...
Business Wire

Intersect ENT Announces Publication of Pooled Analysis of Steroid Releasing Implants in Patients Following Frontal Sinus Surgery

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced publication of a ...
Stockhouse

First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe

Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Helios ...
Becker's ASC

Intersect ENT’s Propel Contour OK’d by EU

Intersect ENT’s sinus implant device Contour received a CE mark from the European Union, the company announced May 20. Contour has an hourglass shape and is placed in the frontal sinuses after surgery ...
Finanznachrichten

Intersect ENT, Inc.: Intersect ENT Receives CE Mark Approval for PROPEL Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery

PROPEL Contour features an innovative hourglass shape, specifically designed for placement in the frontal sinuses (between the eyebrows) following sinus surgery for chronic rhinosinusitis patients.
Stockhouse

Intersect ENT Receives CE Mark Approval for PROPEL® Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery

Localized steroid-releasing sinus implant designed to maintain sinus opening now available in select EU countries Intersect ENT ® , Inc. (Nasdaq: XENT), a global ear, nose and throat ...